# Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

> **NCT02616848** · PHASE1 · UNKNOWN · sponsor: **Istituti Ospitalieri di Cremona** · enrollment: 1 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT02616848
- **Lead sponsor:** Istituti Ospitalieri di Cremona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2015-11
- **Final completion:** —
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2015-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616848, "Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02616848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*